480 related articles for article (PubMed ID: 33409812)
1. Diagnostic and Predictive Role of DLL3 Expression in Gastroenteropancreatic Neuroendocrine Neoplasms.
Liverani C; Bongiovanni A; Mercatali L; Pieri F; Spadazzi C; Miserocchi G; Di Menna G; Foca F; Ravaioli S; De Vita A; Cocchi C; Rossi G; Recine F; Ibrahim T
Endocr Pathol; 2021 Jun; 32(2):309-317. PubMed ID: 33409812
[TBL] [Abstract][Full Text] [Related]
2. Gastroenteropancreatic High-Grade Neuroendocrine Neoplasms: Histology and Molecular Analysis, Two Sides of the Same Coin.
Busico A; Maisonneuve P; Prinzi N; Pusceddu S; Centonze G; Garzone G; Pellegrinelli A; Giacomelli L; Mangogna A; Paolino C; Belfiore A; Kankava K; Perrone F; Tamborini E; Pruneri G; Fazio N; Milione M
Neuroendocrinology; 2020; 110(7-8):616-629. PubMed ID: 31557757
[TBL] [Abstract][Full Text] [Related]
3. A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations.
Elvebakken H; Perren A; Scoazec JY; Tang LH; Federspiel B; Klimstra DS; Vestermark LW; Ali AS; Zlobec I; Myklebust TÅ; Hjortland GO; Langer SW; Gronbaek H; Knigge U; Tiensuu Janson E; Sorbye H
Neuroendocrinology; 2021; 111(9):883-894. PubMed ID: 33002892
[TBL] [Abstract][Full Text] [Related]
4. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
[TBL] [Abstract][Full Text] [Related]
5. Gastroenteropancreatic grade 3 neuroendocrine tumors: a single entity or a heterogeneous group? A retrospective analysis.
Laffi A; Spada F; Bagnardi V; Frassoni S; Pisa E; Rubino M; Barberis M; Fazio N
J Endocrinol Invest; 2022 Feb; 45(2):317-325. PubMed ID: 34282554
[TBL] [Abstract][Full Text] [Related]
6. Gastroenteropancreatic neuroendocrine neoplasms G3: Novel insights and unmet needs.
Shi M; Fan Z; Xu J; Yang J; Li Y; Gao C; Su P; Wang X; Zhan H
Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188637. PubMed ID: 34678439
[TBL] [Abstract][Full Text] [Related]
7. Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study.
Li J; Lu M; Lu Z; Li Z; Liu Y; Yang L; Li J; Zhang X; Zhou J; Wang X; Gong J; Gao J; Li Y; Shen L
Oncotarget; 2017 Apr; 8(15):25669-25678. PubMed ID: 27788498
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic role and prognostic value of tumor markers in high-grade gastro-enteropancreatic neuroendocrine neoplasms.
Gao C; Fan Z; Yang J; Shi M; Li Y; Zhan H
Pancreatology; 2023 Mar; 23(2):204-212. PubMed ID: 36710224
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapies for well-differentiated grade 3 gastroenteropancreatic neuroendocrine tumors: A new category in the World Health Organization classification.
Xu JX; Wu DH; Ying LW; Hu HG
World J Gastroenterol; 2021 Dec; 27(47):8123-8137. PubMed ID: 35068858
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint markers in gastroenteropancreatic neuroendocrine neoplasia.
Bösch F; Brüwer K; Altendorf-Hofmann A; Auernhammer CJ; Spitzweg C; Westphalen CB; Boeck S; Schubert-Fritschle G; Werner J; Heinemann V; Kirchner T; Angele M; Knösel T
Endocr Relat Cancer; 2019 Mar; 26(3):293-301. PubMed ID: 30608901
[TBL] [Abstract][Full Text] [Related]
11. Expression and clinical value of CXCR4 in high grade gastroenteropancreatic neuroendocrine neoplasms.
Pang C; Li Y; Shi M; Fan Z; Gao X; Meng Y; Liu S; Gao C; Su P; Wang X; Zhan H
Front Endocrinol (Lausanne); 2024; 15():1281622. PubMed ID: 38524630
[TBL] [Abstract][Full Text] [Related]
12. Aberrant Expression of Long Non Coding RNA HOTAIR and De-Regulation of the Paralogous 13 HOX Genes Are Strongly Associated with Aggressive Behavior of Gastro-Entero-Pancreatic Neuroendocrine Tumors.
Di Mauro A; Scognamiglio G; Aquino G; Cerrone M; Liguori G; Clemente O; Di Bonito M; Cantile M; Botti G; Tafuto S; Tatangelo F
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34208964
[TBL] [Abstract][Full Text] [Related]
13. Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading.
Cavalcanti E; Armentano R; Valentini AM; Chieppa M; Caruso ML
Cell Death Dis; 2017 Aug; 8(8):e3004. PubMed ID: 28837143
[TBL] [Abstract][Full Text] [Related]
14. [Neuroendocrine neoplasms : Two families with distinct features unified in one classification (German version)].
Klöppel G
Pathologe; 2019 May; 40(3):211-219. PubMed ID: 30969346
[TBL] [Abstract][Full Text] [Related]
15. [Chinese expert consensus on gastroenteropancreatic neuroendocrine neoplasms (2022 edition)].
Expert Committee on Neuroendocrine Neoplasms, Chinese Society of Clinical Oncology
Zhonghua Zhong Liu Za Zhi; 2022 Dec; 44(12):1305-1329. PubMed ID: 36575783
[TBL] [Abstract][Full Text] [Related]
16. Microenvironment and tumor inflammatory features improve prognostic prediction in gastro-entero-pancreatic neuroendocrine neoplasms.
Milione M; Miceli R; Barretta F; Pellegrinelli A; Spaggiari P; Tagliabue G; Centonze G; Paolino C; Mangogna A; Kankava K; Pusceddu S; Giacomelli L; Corti A; Cotsoglou C; Mazzaferro V; Sozzi G; de Braud F; Pruneri G; Anichini A
J Pathol Clin Res; 2019 Oct; 5(4):217-226. PubMed ID: 31136102
[TBL] [Abstract][Full Text] [Related]
17. APOBEC3B High Expression in Gastroenteropancreatic Neuroendocrine Neoplasms and Association With Lymph Metastasis.
Feng C; Zheng Q; Yang Y; Xu M; Lian Y; Huang J; Jiang Y
Appl Immunohistochem Mol Morphol; 2019 Sep; 27(8):599-605. PubMed ID: 30095460
[TBL] [Abstract][Full Text] [Related]
18. Lung Metastases in Patients with Well-Differentiated Gastroenteropancreatic Neuroendocrine Neoplasms: An Appraisal of the Validity of Thoracic Imaging Surveillance.
Daskalakis K; Tsoli M; Srirajaskanthan R; Chatzellis E; Alexandraki K; Angelousi A; Pizanias M; Randeva H; Kaltsas G; Weickert MO
Neuroendocrinology; 2019; 108(4):308-316. PubMed ID: 30673674
[TBL] [Abstract][Full Text] [Related]
19. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
Tang LH; Basturk O; Sue JJ; Klimstra DS
Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
[TBL] [Abstract][Full Text] [Related]
20. NET G3 vs NEC: p53 and Rb1 Immunolabeling in High-grade Gastrointestinal Neuroendocrine Neoplasms - Is It Enough for the Differential Diagnosis?
Dinu A; Aschie M; Cozaru GC; Mitroi AF; Grasa CN; Iordache IE; Deacu M; Orasanu CI; Nicolau AA; Baltatescu GI
J Gastrointestin Liver Dis; 2023 Jun; 32(2):162-169. PubMed ID: 37345605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
